American Century Companies Inc. Raises Position in Embecta Corp. $EMBC

American Century Companies Inc. grew its stake in Embecta Corp. (NASDAQ:EMBC) by 36.3% in the 2nd quarter, Holdings Channel.com reports. The firm owned 5,195,948 shares of the company’s stock after purchasing an additional 1,382,537 shares during the period. American Century Companies Inc. owned about 0.09% of Embecta worth $50,349,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in Embecta by 7.9% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 15,005 shares of the company’s stock valued at $145,000 after buying an additional 1,093 shares during the period. CWM LLC increased its position in Embecta by 16.0% during the second quarter. CWM LLC now owns 8,080 shares of the company’s stock valued at $78,000 after acquiring an additional 1,115 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Embecta by 2.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock valued at $629,000 after acquiring an additional 1,159 shares during the last quarter. SummerHaven Investment Management LLC raised its stake in shares of Embecta by 1.9% in the second quarter. SummerHaven Investment Management LLC now owns 66,313 shares of the company’s stock valued at $643,000 after acquiring an additional 1,268 shares during the period. Finally, Jennison Associates LLC raised its stake in shares of Embecta by 3.1% in the second quarter. Jennison Associates LLC now owns 55,193 shares of the company’s stock valued at $535,000 after acquiring an additional 1,668 shares during the period. Institutional investors own 93.83% of the company’s stock.

Embecta Stock Performance

Shares of NASDAQ EMBC opened at $12.75 on Friday. Embecta Corp. has a 52-week low of $9.20 and a 52-week high of $21.48. The firm has a market capitalization of $745.94 million, a price-to-earnings ratio of 7.82, a PEG ratio of 0.70 and a beta of 1.10. The stock has a 50 day moving average price of $13.92 and a 200 day moving average price of $12.49.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Tuesday, November 25th. The company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.46 by $0.04. Embecta had a negative return on equity of 24.62% and a net margin of 8.83%.The company had revenue of $263.30 million for the quarter, compared to the consensus estimate of $265.66 million. During the same period last year, the business posted $0.45 EPS. Embecta’s quarterly revenue was down 7.7% on a year-over-year basis. Embecta has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts forecast that Embecta Corp. will post 2.85 earnings per share for the current year.

Embecta Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Investors of record on Friday, December 5th will be paid a $0.15 dividend. The ex-dividend date of this dividend is Friday, December 5th. This represents a $0.60 dividend on an annualized basis and a yield of 4.7%. Embecta’s dividend payout ratio is 41.96%.

Analyst Ratings Changes

EMBC has been the subject of a number of recent analyst reports. Wall Street Zen cut shares of Embecta from a “strong-buy” rating to a “buy” rating in a research note on Friday. Weiss Ratings reissued a “hold (c-)” rating on shares of Embecta in a research note on Wednesday, October 8th. Zacks Research cut Embecta from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 7th. Finally, BTIG Research reiterated a “buy” rating on shares of Embecta in a report on Tuesday. One investment analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $19.00.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.